Loading…
Loading…
EXAS (Exact Sciences Corporation) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
EXAS does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for EXAS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EXAS and 80,000+ other tickers.
See exactly how EXAS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EXAS and 80,000+ other tickers.
Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue…
Abbott Laboratories NYSE: ABT gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is solid, the Exact Sciences business has traction, and the near-term margin impairment the acquisition brought is less than expected.
Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.
Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly profit and revenue, but flagged a hit to its 2026 earnings outlook from its recently completed cancer diagnostics acquisition. Investors weighed near-term earnings strength against dilution from the company's roughly $23 billion acquisition of Exact Sciences.
Capricorn Fund Managers Ltd acquired a new stake in shares of Exact Sciences Corporation (NASDAQ: EXAS) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 96,685 shares of the medical research company's stock, valued at approximately $9,819,000. Exact Sciences makes up about 2.4% of Capricorn Fund
Exchange Traded Concepts LLC cut its stake in Exact Sciences Corporation (NASDAQ: EXAS) by 39.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,044 shares of the medical research company's stock after selling 5,932 shares during the quarter. Exchange